WGS Relative Valuation
WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WGS is overvalued; if below, it's undervalued.
Historical Valuation
GeneDx Holdings Corp (WGS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 22.98. The fair price of GeneDx Holdings Corp (WGS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：161.95
Fair
476.32
PE
1Y
3Y
5Y
Trailing
Forward
692.51
EV/EBITDA
GeneDx Holdings Corp. (WGS) has a current EV/EBITDA of 692.51. The 5-year average EV/EBITDA is -80.72. The thresholds are as follows: Strongly Undervalued below -926.61, Undervalued between -926.61 and -503.66, Fairly Valued between 342.23 and -503.66, Overvalued between 342.23 and 765.17, and Strongly Overvalued above 765.17. The current Forward EV/EBITDA of 692.51 falls within the Overvalued range.
469.38
EV/EBIT
GeneDx Holdings Corp. (WGS) has a current EV/EBIT of 469.38. The 5-year average EV/EBIT is 9.35. The thresholds are as follows: Strongly Undervalued below -170.64, Undervalued between -170.64 and -80.64, Fairly Valued between 99.35 and -80.64, Overvalued between 99.35 and 189.34, and Strongly Overvalued above 189.34. The current Forward EV/EBIT of 469.38 falls within the Strongly Overvalued range.
9.22
PS
GeneDx Holdings Corp. (WGS) has a current PS of 9.22. The 5-year average PS is 17.25. The thresholds are as follows: Strongly Undervalued below -61.97, Undervalued between -61.97 and -22.36, Fairly Valued between 56.87 and -22.36, Overvalued between 56.87 and 96.48, and Strongly Overvalued above 96.48. The current Forward PS of 9.22 falls within the Historic Trend Line -Fairly Valued range.
494.90
P/OCF
GeneDx Holdings Corp. (WGS) has a current P/OCF of 494.90. The 5-year average P/OCF is -1018.44. The thresholds are as follows: Strongly Undervalued below -11338.73, Undervalued between -11338.73 and -6178.59, Fairly Valued between 4141.71 and -6178.59, Overvalued between 4141.71 and 9301.85, and Strongly Overvalued above 9301.85. The current Forward P/OCF of 494.90 falls within the Historic Trend Line -Fairly Valued range.
114.18
P/FCF
GeneDx Holdings Corp. (WGS) has a current P/FCF of 114.18. The 5-year average P/FCF is 12.45. The thresholds are as follows: Strongly Undervalued below -55.33, Undervalued between -55.33 and -21.44, Fairly Valued between 46.34 and -21.44, Overvalued between 46.34 and 80.23, and Strongly Overvalued above 80.23. The current Forward P/FCF of 114.18 falls within the Strongly Overvalued range.
GeneDx Holdings Corp (WGS) has a current Price-to-Book (P/B) ratio of 16.01. Compared to its 3-year average P/B ratio of 4.94 , the current P/B ratio is approximately 223.81% higher. Relative to its 5-year average P/B ratio of 3.41, the current P/B ratio is about 369.31% higher. GeneDx Holdings Corp (WGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -100.32%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -70.88% , the current FCF yield is about -100.00% lower.
16.01
P/B
Median3y
4.94
Median5y
3.41
0.33
FCF Yield
Median3y
-100.32
Median5y
-70.88
Competitors Valuation Multiple
The average P/S ratio for WGS's competitors is , providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 51.86%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of WGS increased by 110.71% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 1.11K to 2.20K.
The secondary factor is the Revenue Growth, contributed 51.86%to the performance.
Overall, the performance of WGS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is GeneDx Holdings Corp (WGS) currently overvalued or undervalued?
What is GeneDx Holdings Corp (WGS) fair value?
How does WGS's valuation metrics compare to the industry average?
What is the current P/B ratio for GeneDx Holdings Corp (WGS) as of Dec 05 2025?
What is the current FCF Yield for GeneDx Holdings Corp (WGS) as of Dec 05 2025?
What is the current Forward P/E ratio for GeneDx Holdings Corp (WGS) as of Dec 05 2025?